A two-day dry run for Covid-19 Vaccine program starts today in Andhra Pradesh, Punjab, Gujarat and Assam. Focus on management of possible adverse events after immunisation, and dry runs that include checks on cold storage and transportation arrangements will be part of program that will be carried out in the chosen districts in each state.
All the four states will report their observations to the centre recorded during the program. The government plans to cover 30 crore people in the first phase when it rolls out a vaccine for coronavirus.
A total of 2,360 training sessions have been held so far, and 7,000 officials have been trained, including medical officers and vaccinators.
In Andhra Pradesh, the dry run that will take place in Krishna district is aimed at testing the planned operations and the laid-out mechanisms in the state, Health Commissioner Katamaneni Bhaskar told reporters on Sunday.
“It will provide insights into any gaps or bottlenecks so that those could be addressed before the commencement of the actual drive,” he was quoted as saying by news agency PTI.
Across the four states, five sessions will be held at identified locations with 25 test pre-identified beneficiaries – healthcare workers – for each session.
Feasibility of Co-WIN, an electronic application that identifies beneficiaries, and prerequisites for vaccine introduction as per operational guidelines will be assessed.
AEFI (Adverse Event Following Immunisation) panels will be formed and treatment centres will also be identified if the vaccine triggers an adverse response in any of the beneficiaries.
India is likely to see the Oxford-AstraZeneca Covid-19 vaccine being approved for emergency use in next few days as the updated data submitted by Serum Institute of India (SII) appears “satisfactory”, top government sources said.
Once evaluation of data is complete, the regulator may not wait for the vaccine to get approval from UK’s Medicines and Healthcare products Regulatory Agency (MHRA).
“We can take our regulatory decisions independently. The company has submitted the same data here from clinical trials in the UK and Brazil and rolling reviews are going on. The updated information shared by Serum Institute also appears satisfactory. We are hopeful that based on regulatory assessment, the vaccine will be approved in a day or two,” a senior official told TOI.